아포토시스 어세이 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 수법별, 분석 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Apoptosis Assay Market Growth & Trends:

The global apoptosis assay market size is expected to reach USD 10.57 billion by 2030, expanding at a CAGR of 8.65%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.

The flow cytometry segment dominated the market and accounted for the largest revenue share in 2019. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2019 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

Apoptosis Assay Market Report Highlights:

• The kits segment dominated the market and accounted for a revenue share of around 54.71% owing to increasing investment by key market players
• Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market
• Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth
• The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth
• North America has dominated the market in terms of revenue share in 2024, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technique
  • 1.2.3. Assay Type
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Apoptosis Assay Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Cancer and Chronic Diseases
    • 3.2.1.2. Advancements in Molecular Biology and Drug Discovery
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Assay Techniques
    • 3.2.2.2. Lack of Skilled Professionals
• 3.3. Apoptosis Assay Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Apoptosis Assay Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Apoptosis Assay Market Product Movement Analysis
• 4.3. Global Apoptosis Assay Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Kits
  • 4.4.1. Kits Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.5. Reagents
  • 4.5.1. Reagents Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.6. Instruments
  • 4.6.1. Instruments Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Apoptosis Assay Market: Technique Estimates & Trend Analysis

• 5.1. Technique Segment Dashboard
• 5.2. Global Apoptosis Assay Market Technique Movement Analysis
• 5.3. Global Apoptosis Assay Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
• 5.4. Flow Cytometry
  • 5.4.1. Flow Cytometry Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.5. Fluorescence Microscopy
  • 5.5.1. Fluorescence Microscopy Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.6. Spectrophotometry
  • 5.6.1. Spectrophotometry Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.7. Other Techniques
  • 5.7.1. Other Techniques Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Apoptosis Assay Market: Assay Type Estimates & Trend Analysis

• 6.1. Assay Type Segment Dashboard
• 6.2. Global Apoptosis Assay Market Assay Type Movement Analysis
• 6.3. Global Apoptosis Assay Market Size & Trend Analysis, by Assay Type, 2018 to 2030 (USD Million)
• 6.4. Caspase Assays
  • 6.4.1. Caspase Assays Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.5. DNA Fragmentation Assays
  • 6.5.1. DNA Fragmentation Assays Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.6. Cell Permeability Assays
  • 6.6.1. Cell Permeability Assays Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.7. Mitochondrial Assays
  • 6.7.1. Mitochondrial Assays Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)

Chapter 7. Apoptosis Assay Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Apoptosis Assay Market End Use Movement Analysis
• 7.3. Global Apoptosis Assay Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & Biotechnology Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.5. Hospital & Diagnostic Laboratories
  • 7.5.1. Hospital & Diagnostic Laboratories Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & Research Institutes Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 8. Apoptosis Assay Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Strategy Mapping
• 9.4. Participants Overview
  • 9.4.1. Thermo Fisher Scientific, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Bio-Rad Laboratories
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Bio-Techne
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Biotium
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. GeneCopoeia, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Becton, Dickinson & Company (BD)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Promega Corporation
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Sartorius AG
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Merck KGaA
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Abcam plc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Takara Bio Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives